{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T19:13:24Z","timestamp":1775330004297,"version":"3.50.1"},"reference-count":34,"publisher":"Informa UK Limited","issue":"9","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Safety"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1080\/14740338.2024.2387318","type":"journal-article","created":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T13:59:35Z","timestamp":1722866375000},"page":"1109-1114","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Approved treatments for neovascular age-related macular degeneration: current safety and future directions"],"prefix":"10.1080","volume":"23","author":[{"given":"Hannah","family":"Khan","sequence":"first","affiliation":[{"name":"Reno School of Medicine, University of Nevada, Reno, NV, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aamir A.","family":"Aziz","sequence":"additional","affiliation":[{"name":"Reno School of Medicine, University of Nevada, Reno, NV, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoha","family":"Khanani","sequence":"additional","affiliation":[{"name":"Sierra Eye Associates, Reno, NV, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huma","family":"Khan","sequence":"additional","affiliation":[{"name":"Sierra Eye Associates, Reno, NV, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ohidul","family":"Mojumder","sequence":"additional","affiliation":[{"name":"Sierra Eye Associates, Reno, NV, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greggory M.","family":"Gahn","sequence":"additional","affiliation":[{"name":"Sierra Eye Associates, Reno, NV, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arshad M.","family":"Khanani","sequence":"additional","affiliation":[{"name":"Reno School of Medicine, University of Nevada, Reno, NV, USA"},{"name":"Sierra Eye Associates, Reno, NV, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2024,8,5]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(13)70145-1"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.13343"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.07.038"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054481"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062655"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S86269"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2019.09.009"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2020.2699"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.03.023"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2021.100076"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00010-1"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2024.02.014"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-023-02553-5"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.iae.0000242842.14624.e7"},{"key":"e_1_3_5_17_1","unstructured":"Papadopoulos N Martin J Ruan Q et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF trap ranibizumab and bevacizumab. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3338918\/"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.03.036"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2021.09.016"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-023-00446-z"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1159\/000513048"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.06.028"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.04.017"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.11.011"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S425709"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1381"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.03.053"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61501-9"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-007-0660-z"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3181884fd2"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.09.006"},{"key":"e_1_3_5_33_1","volume-title":"Presented at: American Academy of Ophthalmology Annual Meeting 2022","author":"Lanzetta P","year":"2022","unstructured":"Lanzetta P. On behalf of the PULSAR study investigators. Intravitreal aflibercept injection 8 Mg for namd: 48-week results from the phase III PULSAR trial. In: Presented at: American Academy of Ophthalmology Annual Meeting 2022; Chicago, IL, 30 September\u20133 October, 2022."},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-022-00488-w"},{"key":"e_1_3_5_35_1","volume-title":"Presented at: American Academy of Ophthalmology Annual Meeting 2022","author":"Bressler S","year":"2022","unstructured":"Bressler S. MYL-1701P (proposed biosimilar aflibercept) compared to Eylea in DME: outcomes from the phase 3 INSIGHT study. In: Presented at: American Academy of Ophthalmology Annual Meeting 2022; 30 September\u20133O ctober; Chicago, IL. 2022."},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2023-001561"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2006.03.036"}],"container-title":["Expert Opinion on Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14740338.2024.2387318","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T14:12:36Z","timestamp":1732889556000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14740338.2024.2387318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,5]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1080\/14740338.2024.2387318"],"URL":"https:\/\/doi.org\/10.1080\/14740338.2024.2387318","relation":{},"ISSN":["1474-0338","1744-764X"],"issn-type":[{"value":"1474-0338","type":"print"},{"value":"1744-764X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,5]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-12-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}